Table 3.

Outcomes of the propensity score matched population

Variables	Propensity score matched cohort		P
	RPD (n = 105)	OPD (n = 210)
DFS			0.345
1-year DFS, (95% CI)	53.9% (45.1–64.4%)	45.9% (39.5–53.3%)
3-year DFS, (95% CI)	17.1% (9.5–30.8%)	18.5% (13.1–26.1%)
Recurrence, n (%)	62 (59.0%)	138 (65.7%)	0.587
Recurrence pattern, n (%)
Local only	16 (25.8%)	41 (29.7%)	0.572
Liver metastasis only	15 (24.2%)	35 (25.4%)	0.860
Local and liver metastasis	16 (25.8%)	50 (36.2%)	0.147
Other	15 (24.2%)	12 (8.7%)	0.003
Post recurrence chemotherapy	43 (69.4%)	75 (54.3%)	0.046
OS			0.087
1-year OS, (95% CI )	76.0% (68.2–84.7%)	69.5% (63.4–76.1%)
3-year OS, (95% CI )	33.0% (23.3–46.8%)	29.4% (23.1–37.3%)

Other, include lung metastasis, bone metastasis, trocar or incision implantation metastasis and malignant ascites

OPD open pancreatoduodenectomy, RPD robotic-assisted pancreatoduodenectomy, DFS disease-free survival, OS overall survival